PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
1.95%
Revenue growth under 50% of MCHP's 19.16%. Michael Burry would suspect a deteriorating sales pipeline or weaker brand.
1.45%
Gross profit growth under 50% of MCHP's 12.82%. Michael Burry would be concerned about a severe competitive disadvantage.
-0.33%
Negative EBIT growth while MCHP is at 14.18%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-0.33%
Negative operating income growth while MCHP is at 12.74%. Joel Greenblatt would press for urgent turnaround measures.
0.90%
Net income growth under 50% of MCHP's 15.09%. Michael Burry would suspect the firm is falling well behind a key competitor.
1.79%
EPS growth under 50% of MCHP's 16.67%. Michael Burry would suspect deeper structural issues or share dilution limiting per-share gains.
1.82%
Diluted EPS growth under 50% of MCHP's 12.50%. Michael Burry would worry about an eroding competitive position or excessive dilution.
-0.94%
Share reduction while MCHP is at 0.41%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-1.17%
Reduced diluted shares while MCHP is at 0.33%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-1.03%
Dividend reduction while MCHP stands at 0.30%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
22.29%
OCF growth 1.25-1.5x MCHP's 18.61%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
10.25%
FCF growth under 50% of MCHP's 27.29%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
163.00%
10Y revenue/share CAGR 1.25-1.5x MCHP's 124.26%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.
25.66%
5Y revenue/share CAGR under 50% of MCHP's 89.05%. Michael Burry would suspect a significant competitive gap or product weakness.
17.83%
3Y revenue/share CAGR under 50% of MCHP's 71.99%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
66.82%
10Y OCF/share CAGR at 50-75% of MCHP's 100.10%. Martin Whitman might fear a structural deficiency in operational efficiency.
32.66%
5Y OCF/share CAGR at 50-75% of MCHP's 62.98%. Martin Whitman would question if the firm lags in monetizing revenue effectively.
38.83%
3Y OCF/share CAGR at 50-75% of MCHP's 74.57%. Martin Whitman would suspect weaker recent execution or product competitiveness.
628.47%
Net income/share CAGR above 1.5x MCHP's 130.60% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
-62.18%
Negative 5Y net income/share CAGR while MCHP is 76.49%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
30.50%
Below 50% of MCHP's 97.68%. Michael Burry suspects a steep short-term disadvantage in bottom-line expansion.
33.35%
Below 50% of MCHP's 127.40%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
14.54%
5Y equity/share CAGR is in line with MCHP's 14.12%. Walter Schloss would see parallel mid-term profitability and retention policies.
24.70%
Positive short-term equity growth while MCHP is negative. John Neff sees a strong advantage in near-term net worth buildup.
528.07%
Dividend/share CAGR of 528.07% while MCHP is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
328.75%
5Y dividend/share CAGR above 1.5x MCHP's 174.49%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.
29.76%
3Y dividend/share CAGR above 1.5x MCHP's 16.28%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.
6.63%
AR growth well above MCHP's 4.78%. Michael Burry fears inflated revenue or higher default risk in the near future.
5.01%
Inventory shrinking or stable vs. MCHP's 30.00%. David Dodd confirms the company’s supply-chain is more efficient if sales are unaffected.
28.46%
Asset growth above 1.5x MCHP's 4.27%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.09%
Similar to MCHP's 4.02%. Walter Schloss finds parallel capital usage or profit distribution strategies.
No Data
No Data available this quarter, please select a different quarter.
0.47%
R&D dropping or stable vs. MCHP's 13.10%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
3.79%
SG&A growth well above MCHP's 7.27%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.